Login to Your Account



Clinic Roundup


Thursday, December 1, 2011
• Cytokinetics Inc., of South San Francisco, reported data from the first cohort of an ongoing Phase II study of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), showing that the drug was well tolerated when dosed daily as a single agent for two weeks. Those data were presented at the International Symposium on ALS/MND in Sydney, Australia. Cytokinetics recently started the second cohort of the study, which is expected to test the drug in 24 ALS patients who are receiving riluzole. CK-2017357 is a selective fast skeletal muscle troponin complex activator.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription